AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00756015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Motion Protocol
Description: Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
Study NCT00756015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immobilization
Description: Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
Study NCT00625794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Description: 8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).
Study NCT00625794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: 8 weeks or counseling
Study NCT02091973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus dosing to target tough level 6-10 mg/ml
Study NCT02091973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus dosing to target tough level 5-10 ng/ml
Study NCT03648827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered as per the dose and schedule specified in the arm.
Study NCT03132012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indoor tanning intervention
Description: 6 Web-based modules that focus on preventing skin cancer through sun protection and indoor tanning reduction using the Theory of Planned Behavior and Prospect Theory
Study NCT03038919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: Bi-weekly intramuscular injection of testosterone cypionate 200mg.
Study NCT03038919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard nutrition and physical therapy at ICU
Description: follow-up of the patient without use of testosterone cypionate
Study NCT03132012 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care control
Description: One website with content similar to those available in dermatology offices on skin cancer prevention
Study NCT02027376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Study NCT02027376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT03654066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botox injection in the LES
Study NCT03654066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscope balloon dilator
Description: Distal esophageal dilation
Study NCT03654066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient reported outcomes
Description: Subjects will complete two patient reported outcome measures (Eckardt and MADS).
Study NCT03038919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard nutrition and physical therapy at ICU
Description: follow-up of the patient without use of testosterone cypionate
Study NCT03654066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Barium esophagram
Description: Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium
Study NCT03283956 — intervention group
Intervention type: DEVICE
Intervention: Patient records
Description: Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7
Study NCT03848104 — intervention group
Intervention type: OTHER
Intervention: bone and joint infection treated with cefoxitin
Description: the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection
Study NCT01782911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: The patients will take 2 g of resveratrol per day for 40 days.
Study NCT01782911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: The patients will take placebo for 40 days.
Study NCT04115254 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided Linac
Description: Radiation will be delivered on an MR-guided Linear Accelerator
Study NCT02994706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.
Study NCT02994706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Care
Description: Participants selected for this arm will continue to receive routine clinical care.
Study NCT03810885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread with reduced salt content
Description: Bread with gradually lowered salt content
Study NCT04379271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838
Description: Tablets will be taken BID with a glass of water (if possible); one tablet each in the morning (15 to 50 min before a meal if applicable), and in the evening (2 hours after any meal if applicable).~If the patient is intubated for ventilation, IMP is to be given via a gastric tube. The tablet has no coating and a homogeneous content and can be crushed into smaller pieces (if necessary) for dosing via gastric tube.
Study NCT04379271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for IMU-838
Study NCT04655976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cobolimab
Description: Cobolimab will be administered.
Study NCT04655976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study NCT04655976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered.
Study NCT04655976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered.
Study NCT03260322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous
Study NCT03810885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Participants will receive information on how to lower salt and increase potassium intake
Study NCT03810885 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bread with standard salt content
Description: Bread with normal salt content
Study NCT02808377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Pelvic Organ Pessary
Description: In participants randomized to intervention, the SPOP will be placed at the completion of surgery, following routine placement of IDC and prior to placement of vaginal pack. The SPOP is available in 4 sizes and the surgeon will select the appropriate size so that the SPOP rests snugly without undue tension inside the hymeneal remnant. The SPOP is sutured in place with 2/0 Vicryl to prevent dislodgement at the level of the hymen.
Study NCT02572609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol hydrochloride soft pastille
Study NCT03260322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous
Study NCT02236013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral
Study NCT03906747 — intervention group
Intervention type: OTHER
Intervention: Interviews, questionnaire and focused group discussions
Description: To determine the effectiveness of the quality of care as perceived by relatives, we will perform a survey during the ED stay, with the next-of-kin to patients who was on the EOL pathway using a questionnaire developed for ED settings. The questionnaire will be administered by the research assistant face-to-face in the emergency department to assess the quality of care and the level of support provided to patients and their families in the last days of life.~We will also determine the level of staff's knowledge and perception of the EOL care using a locally-designed self-administered anonymous survey.~A focus group discussion (FGD) will be formed in each hospital to identify the gaps to the current EOL care by structured questionnaire. The group will also make recommendations to improve the quality of the EOL care. There will be separate FGD for: (i) healthcare professionals (ii) family members and (iii) general practitioners who will care for the patient if terminally discharged.
Study NCT03906747 — intervention group
Intervention type: OTHER
Intervention: Review of medical records
Description: Electronic medical records will be reviewed to collect the following data:~1. Proportion of patients who fits criteria of EOL who died within 48 hours;~2. Proportion of patients on EOL pathway who have documentation that patient and/or family are given opportunities to discuss an individualised care plan;~3. Proportion of patients on EOL pathway who have documentation of an individualised care plan that is followed;~4. Proportion of patients on EOL pathway who have symptoms who are prescribed with medicines with individualised indications for use, dosage and route of administration
Study NCT00819234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pramlintide and placebo metreleptin twice daily
Study NCT00819234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide and Metreleptin
Description: Subcutaneous injection, twice daily
Study NCT03174938 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Flutemetamol F18 Injection
Description: PET imaging of Abeta amyloid
Study NCT03174938 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-RO6958948
Description: PET imaging of Tau aggregates
Study NCT02572609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucosolvan ® adult syrup
Study NCT02095067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video consultation
Study NCT02372240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLX1570 and dexamethasone
Study NCT01365065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 400mg (4 x 100mg) orally daily for 14 days
Study NCT00036296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talampanel
Description: 75mg per day divided into 3 doses for 22 days
Study NCT00036296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: talampanel
Description: 75mg per day divided into 3 doses for 22 days
Study NCT04398251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40mg Tab
Description: For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week.
Study NCT04398251 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-drug control group
Description: All patients in the group are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly
Study NCT03784417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided laser ablation
Description: EUS-guided LA will be performed with an endoscopic ultrasound guided approach using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge flexible needle that is inserted in the working channel of the echoendoscope.
Study NCT03174938 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Elecsys (Roche) Abeta42, Ttau and Ptau
Description: Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
Study NCT03652376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)
Study NCT03053583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope blade
Description: The POGO score assesses the percent of the glottic opening that can be seen with each blade
Study NCT04112888 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Collagen
Description: Patients will receive 3 to 5 collagen infiltrations in the scar once per week. Patients with episiotomy will receive 3 collagen infiltrations while patients who underwent a cesarean section will receive 5 collagen infiltrations. The infiltration will be done by tunneling technique, that is, it will be applied along the scar, placing the needle almost tangential to the entire length of the area, then it will be injected and at the same time the needle will be removed. Infiltrations will be carried out intradermally, previously performing asepsis in the area to be infiltrated. 2 ml syringes will be used to infiltrate the episiotomy scars (we will use 1 vial of 2 ml ) and 5 ml for cesarean scars (2 vials of 2 ml ) and sterile needles of 30G, 13mm.
Study NCT04112888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation sessions
Description: Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. There will be two sessions per week for four weeks. The sessions will last 45 minutes.
Study NCT04112888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation sessions
Description: Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. There will be two sessions per week for four weeks. The sessions will last 45 minutes.
Study NCT03975062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: 150 mg twice daily (BID)
Study NCT03975062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dabigatran etexilate
Description: 150 mg twice daily (BID)
Study NCT04020328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg+prednisone 0.5mg/kg/d
Description: Leflunomide plus low dose glucocorticoids to have the immunosuppressive therapy to those progressive IgA nephropathy with eGFR\<50ml/min
Study NCT01822496 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
Study NCT03174938 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
Description: Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
Study NCT03805958 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: realtime ultrasonography
Description: Applying realtime ultrasound during the combined anesthesia
Study NCT03805958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prescan ultrasonography
Description: Applying realtime ultrasound before the combined anesthesia
Study NCT05437471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNRH Analoge, Duphaston, Letrozole
Description: GNRH Analoge, Duphaston, Letrozole
Study NCT05437471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GNRH Analoge, Duphaston, Letrozole
Description: GNRH Analoge, Duphaston, Letrozole
Study NCT02646046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combi lone-CPR
Description: When study participants meet the arrest victim (simulated), they start chest compression and call for help to EMS at the same time, then continue the chest compression and 2 breath alternatively until the EMS arrival
Study NCT02646046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional lone-CPR
Description: When study participants meet the arrest victim (simulated), they first call for help to EMS and then start chest compression and 2 breath alternatively until the EMS arrival
Study NCT01237392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact ultrasonic debridement device
Description: Cavitational ultrasound wound debridement device
Study NCT01388543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days
Study NCT00630864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fx-1006A
Description: During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
Study NCT01113229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: two misoprostol tablets taken orally (400µg)
Study NCT01113229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: two misoprostol tablets taken orally (400µg)
Study NCT01822496 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: 30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
Study NCT01822496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22.
Study NCT01822496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22.
Study NCT01822496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
Study NCT01822496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
Study NCT01822496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 250 mg, orally, twice daily for four 3-week cycles (12 weeks in total)
Study NCT01822496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg, orally, once daily for four 3-week cycles (12 weeks in total)
Study NCT01822496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
Study NCT01822496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
Study NCT01822496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22.
Study NCT01822496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22.